Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
Status:
Withdrawn
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the safety, best dose and effectiveness of targeted gene
therapy combined with isolated limb infusion (ILI) of melphalan and dactinomycin for treating
patients with advanced extremity melanoma that cannot be removed by surgery. Adding gene
therapy to a standard chemotherapy regimen in the isolated limb may enhance anti-cancer
effects by inducing a systemic immune response against the tumor cells.